Key result
Nadolol cuts cardiac events ~58% in LQTS, proving most effective for LQT2 patients.
Why the study?
Previous studies suggested that beta-blockers exhibit different efficacies for reducing cardiac events in patients with LQTS.
Do different beta-blockers exhibit different efficacies for reducing the risk of cardiac events in patients with Long QT Syndrome 1-3?
Population
Patients with LQTS 1–3
Comparison
Different beta-blockers (atenolol, propranolol, metoprolol, and nadolol)
Design
Network meta-analysis
Authors
Loading...
Nadolol should be prioritized in LQT2 to reduce events; extends evidence for genotype-specific beta-blocker selection in Long QT Syndrome.
Meta-Analysis (n=11,569)
Do different beta-blockers exhibit different efficacies for reducing the risk of cardiac events in patients with Long QT Syndrome 1-3?
Effect estimate: HR 0.42 (95% CI 0.25-0.70)
Nadolol appears to be a relatively effective beta-blocker for preventing recurrent cardiac events in patients with LQT2.
Han et al. (2020) conducted a meta-analysis in Long QT Syndrome (LQTS) 1-3 (n=11,569). Nadolol vs. Other beta-blockers or no beta-blockers was evaluated on Cardiac events (syncope, aborted cardiac arrest, and sudden cardiac death) (HR 0.42, 95% CI 0.25-0.70). Nadolol significantly reduced the risk of cardiac events in patients with Long QT Syndrome (HR 0.42) and was identified as the most effective beta-blocker therapy for LQT2 patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: